Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

Squamous cell carcinoma of the lung (LUSC) stands as the second most prevalent form of non–small cell lung cancer (NSCLC), constituting 20%-30% of patients with ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...